Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1802 1
1885 1
1886 2
1889 3
1890 1
1894 2
1895 1
1896 11
1897 15
1898 1
1899 4
1901 1
1903 1
1905 1
1908 1
1909 5
1910 11
1911 10
1912 10
1913 6
1915 9
1916 11
1917 7
1941 1
1951 2
1977 1
2003 1
2004 1
2006 2
2007 1
2008 5
2009 1
2010 3
2011 5
2012 2
2013 5
2014 9
2015 9
2016 13
2017 20
2018 26
2019 47
2020 76
2021 83
2022 70
2023 20
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31974683

474 results

Results by year

Filters applied: . Clear all
Page 1
Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H. Naito Y, et al. Int J Clin Oncol. 2020 Mar;25(3):403-417. doi: 10.1007/s10147-019-01610-y. Epub 2020 Jan 24. Int J Clin Oncol. 2020. PMID: 31974683 Free PMC article.
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.
Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T. Mishima S, et al. Int J Clin Oncol. 2020 Feb;25(2):217-239. doi: 10.1007/s10147-019-01498-8. Epub 2019 Jul 8. Int J Clin Oncol. 2020. PMID: 31286289 Free PMC article.
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. Yoshino T, et al. Ann Oncol. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. Epub 2020 Apr 6. Ann Oncol. 2020. PMID: 32272210 Free article.
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Doebele RC, et al. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838007 Free PMC article.
The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR, Beniuga G, Craciun L, Creytens D, Dedeurwaerdere F, Delvenne P, Demetter P, De Wiest B, Dewinne K, Habran L, Pauwels P, Theate I, Vander Borght S, Van Der Steen K, Weynand B. Van Bockstal MR, et al. Pathobiology. 2022;89(6):393-406. doi: 10.1159/000522426. Epub 2022 Mar 29. Pathobiology. 2022. PMID: 35350025 Free article.
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS. Laetsch TW, et al. Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Lancet Oncol. 2018. PMID: 29606586 Free PMC article. Clinical Trial.
474 results